Industry
U.S. biotech Axiom chooses Hong Kong over Nasdaq for first listing
U.S. biotech Axiom Biosciences has chosen Hong Kong, not a U.S. exchange, for its first stock market listing. The San Diego-based company is pursuing a Hong Kong listing in 2027 and is considering a secondary U.S. listing in 2029. Axiom expects Hong Kong to provide access to specialist biotech investors and expand cooperation with Asian clinical trial and commercialization partners amid shifting global biotech financing conditions.
